Status:
COMPLETED
Clinical Performance of SE-SPTM-PCR in Detecting Hcmv-miR-UL22A-5p After Hematopoietic Stem Cell Transplantation
Lead Sponsor:
Ting YANG
Conditions:
Cytomegalovirus Infections
Hematopoietic Stem Cell Transplantation (HSCT)
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to evaluate the clinical performance of a novel microRNA-based detection platform, SE-SPTM-PCR, for identifying cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell...
Detailed Description
Cytomegalovirus (CMV) reactivation is a frequent and serious complication after allogeneic hematopoietic stem cell transplantation (HSCT), potentially leading to CMV disease, graft-versus-host disease...
Eligibility Criteria
Inclusion
- Patients who received allogeneic hematopoietic stem cell transplantation (HSCT)
- Availability of archived plasma samples collected within 100 days post-transplant
- Documented CMV DNA testing results corresponding to the plasma sample
- Age ≥ 18 years
Exclusion
- Lack of corresponding CMV DNA testing results
- Inadequate volume or quality of archived plasma sample for analysis
- Concurrent active infections with other viruses (e.g., EBV, HBV, HCV) at time of plasma collection
- Patients who received investigational antiviral therapy within 2 weeks prior to sample collection
Key Trial Info
Start Date :
May 6 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 18 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT07181330
Start Date
May 6 2021
End Date
June 18 2025
Last Update
September 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350001